BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rencarex girentuximab: Phase III ongoing

An IDMC recommended that Wilex skip a planned interim analysis and proceed directly to the final analysis in the double-blind, placebo-controlled Phase III ARISER trial of Rencarex girentuximab to treat clear cell renal cell carcinoma (ccRCC). According to the company, a decline in the trial's rate of recurrence over the past year led the IDMC to conclude that the trial is mature enough to...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >